Cyclogest Leggangastíll 400 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cyclogest leggangastíll 400 mg

gedeon richter plc.* - progesteronum inn - leggangastíll - 400 mg

Visanne Tafla 2 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

visanne tafla 2 mg

bayer ab* - dienogestum inn - tafla - 2 mg

Qlaira Filmuhúðuð tafla Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

qlaira filmuhúðuð tafla

bayer ab - estradiolum valerat; dienogestum inn; estradiolum valerat - filmuhúðuð tafla

Cyclogyl 1% Augndropar, lausn 10 mg/ ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cyclogyl 1% augndropar, lausn 10 mg/ ml

alcon nordic a/s - cyclopentolatum hýdróklóríð - augndropar, lausn - 10 mg/ ml

Decortin H Tafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

decortin h tafla 5 mg

merck ab - prednisolonum inn - tafla - 5 mg

Mekinist Evrópusambandið - íslenska - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanoma - Æxlishemjandi lyf - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ekki lítinn klefa lungnakrabbamein (nsclc)trametinib ásamt dabrafenib er ætlað fyrir meðferð fullorðinn sjúklinga með langt ekki lítið klefi lungnakrabbamein með meÐferÐ v600 stökkbreytingu.

Braftovi Evrópusambandið - íslenska - EMA (European Medicines Agency)

braftovi

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Æxlishemjandi lyf - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Mektovi Evrópusambandið - íslenska - EMA (European Medicines Agency)

mektovi

pierre fabre medicament - binimetinib - melanoma - Æxlishemjandi lyf - binimetinib ásamt encorafenib er ætlað fyrir meðferð fullorðinn sjúklinga með unresectable eða sjúklingum húðkrabbanum með meÐferÐ v600 stökkbreytingu.

Cosopt sine Augndropar, lausn 20 mg/ml+5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cosopt sine augndropar, lausn 20 mg/ml+5 mg/ml

santen oy* - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml+5 mg/ml

Sporanox Hart hylki 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sporanox hart hylki 100 mg

janssen-cilag ab - itraconazolum inn - hart hylki - 100 mg